Jpmorgan Chase & CO Vaxart, Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Vaxart, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,214 shares of VXRT stock, worth $1,594. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,214
Previous 122,571
98.19%
Holding current value
$1,594
Previous $159,000
99.37%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding VXRT
# of Institutions
112Shares Held
40.5MCall Options Held
96.7KPut Options Held
239K-
Sio Capital Management, LLC New York, NY14.8MShares$10.6 Million3.69% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.95MShares$7.16 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.99MShares$2.87 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.2MShares$1.58 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.77MShares$1.28 Million0.0% of portfolio
About Vaxart, Inc.
- Ticker VXRT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 126,506,000
- Market Cap $91.1M
- Description
- Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...